High blood pressure and type 2 diabetes often go hand in hand, creating serious health challenges for millions of people worldwide. Managing both conditions effectively is essential because uncontrolled blood pressure can accelerate kidney damage, a complication already common among people living with diabetes.
A recent study presented at a major kidney health conference has raised concerns about a widely prescribed group of blood pressure medications known as dihydropyridine calcium-channel blockers (DCCBs). Researchers found that these medications may be associated with a higher risk of kidney disease progression in patients with type 2 diabetes, even when they are receiving modern kidney-protective treatments.
While the findings do not prove that the medications directly cause kidney damage, they highlight the need for further investigation and may influence future treatment decisions for patients with diabetic kidney disease.
Diabetic kidney disease (DKD) is one of the most common complications of type 2 diabetes. Over time, elevated blood sugar levels can damage the kidneys' filtering system, reducing their ability to remove waste and excess fluid from the body.
If left untreated, diabetic kidney disease can progress to chronic kidney disease or even kidney failure, requiring dialysis or a kidney transplant. Because of this risk, healthcare providers often use a combination of medications to protect kidney function while controlling blood pressure and blood sugar levels.
Dihydropyridine calcium-channel blockers are a class of medications frequently prescribed to lower blood pressure. They work by relaxing and widening blood vessels, allowing blood to flow more easily and reducing strain on the cardiovascular system.
Some commonly prescribed medications in this category include:
These drugs are often used when additional blood pressure control is needed beyond first-line therapies.
The study was presented at the European Renal Association Congress held in Glasgow, Scotland. Researchers analyzed health data from more than 31,000 adults living with type 2 diabetes between 2016 and 2021.
All participants were already receiving two important categories of medications commonly used to protect kidney health:
These medications have significantly improved outcomes for patients with diabetic kidney disease by helping reduce pressure within the kidneys and lowering the risk of kidney failure.
Among the study population, approximately 39% were also prescribed a dihydropyridine calcium-channel blocker.
Researchers monitored participants for an average of around three and a half years to evaluate long-term kidney outcomes.
The analysis revealed that patients taking DCCBs alongside kidney-protective medications experienced a 33% higher risk of major kidney-related complications compared with those who were not taking these drugs.
One of the most notable findings was that the increased risk remained evident even among patients receiving SGLT2 inhibitors, medications that are widely recognized for their kidney-protective benefits.
Researchers had initially expected these protective therapies to offset any potential negative effects associated with DCCBs. However, the data suggested that the elevated risk continued despite the use of modern treatment strategies.
Scientists believe the explanation may lie in how these medications influence blood flow within the kidneys.
The kidneys rely on a delicate balance of pressure to filter blood efficiently. According to researchers, DCCBs may relax blood vessels entering the kidneys more than those leaving them. This imbalance could increase pressure within the kidney's filtering structures.
Over time, sustained pressure may contribute to kidney damage and accelerate disease progression in susceptible individuals, particularly those already dealing with diabetic kidney disease.
Although this theory is biologically plausible, researchers emphasize that more studies are necessary to fully understand the relationship.
Despite the concerning findings, experts stress that the study has several limitations.
Most importantly, the research was observational. Observational studies can identify associations between factors but cannot prove direct cause and effect.
This means that while DCCB use was linked to a higher risk of kidney complications, the study cannot definitively conclude that the medications themselves caused the damage.
Other factors, including underlying health conditions, disease severity, and treatment variations, may have influenced the results.
To establish a clearer understanding, researchers say randomized controlled trials and prospective studies are needed.
Patients currently taking amlodipine, nifedipine, felodipine, or similar medications should not stop treatment based solely on this study.
Blood pressure control remains a critical part of managing diabetes and preventing complications. Abruptly discontinuing medication without medical supervision can lead to dangerous increases in blood pressure and other health risks.
Instead, patients who have concerns should discuss the findings with their healthcare provider. Physicians can evaluate individual risk factors, review current treatment plans, and determine whether any medication adjustments are appropriate.
Healthcare decisions should always be based on a complete assessment of a patient's overall health status rather than a single study result.
If future studies confirm these findings, the results could have significant implications for diabetes and kidney disease management.
Because DCCBs are commonly prescribed worldwide, even a modest increase in kidney-related risk could affect a large patient population.
Researchers hope that additional clinical trials will clarify whether alternative blood pressure treatments may offer better kidney protection for patients with diabetic kidney disease.
Until more evidence becomes available, healthcare providers are likely to continue weighing the benefits and risks of various blood pressure medications on an individual basis.
The latest research adds an important piece to the ongoing discussion about the safest and most effective ways to manage blood pressure in people with type 2 diabetes and kidney disease.
While dihydropyridine calcium-channel blockers remain valuable medications for many patients, the study suggests there may be potential kidney-related concerns that warrant closer examination.
Further research will be necessary to determine whether these findings should lead to changes in treatment recommendations. In the meantime, patients should continue following their prescribed treatment plans and consult their healthcare providers before making any medication changes.
European Renal Association Congress presentation, June 2026.
This article is intended for informational and educational purposes only and should not be considered medical advice, diagnosis, or treatment. The findings discussed are based on preliminary research presented at a medical conference and have not yet undergone peer review publication. Individual health circumstances vary significantly. Always consult a qualified healthcare professional regarding any medical condition, treatment decision, or medication concern.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.